IgGenix, Inc
WE'RE HIRING: http://iggenix.com/#careers
WE'RE HIRING: http://iggenix.com/#careers
IgGenix, Inc is an early-stage biotechnology company, founded in 2019, backed by $40.00M Series B investment. The company is based in South San Francisco, CA and has garnered support from prominent investors such as Khosla Ventures, Alexandria Venture Investments, Eli Lilly, Sean Parker, and AllerFund. IgGenix stands out for its groundbreaking advances originating from Stanford's laboratory and the collaboration with allergy clinician and researcher Kari Nadeau. The company offers enticing opportunities for individuals with specialized skills, highlighting their commitment to innovation in the field. For venture capitalists seeking to invest in the healthcare industry, IgGenix's unique positioning and the impressive support it has garnered make it a compelling prospect.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $40.00M | 5 |
|
06 Feb 2023 |
| Series A | Unknown | 1 |
|
18 Apr 2022 |
| Series A | $25.00M | 4 |
|
27 Jul 2021 |
| Series A | $10.00M | - | 04 Aug 2020 |
No recent news or press coverage available for IgGenix, Inc.
We care about your data, and we'd love to use cookies make your experience better.
